Co-Founder of Berkley HeartLab to Lead Medical Affairs at Celera

Life Science Partner announces the recruitment of Robert Superko, MD, most recently Executive Director of Genomics and Human Health at St. Joseph’s Hospital of Atlanta’s Translational Research Institute, to Celera.

Celera is a healthcare business delivering personalized disease management through a combination of products and services incorporating proprietary discoveries, including a clinical services business, Berkley HeartLab (BHL).  Celera commercializes a wide range of molecular diagnostic products and technologies to provide personalized disease management in cancer and liver diseases.

Dr. Superko is a world leader in the field of metabolic heart disease diagnosis and treatment, and genomics, which is the ability to tailor treatment specifically to a patient based on their genetic makeup.  He has published over 100 manuscripts and 19 textbook chapters and is the author of BEFORE THE HEART ATTACKS, a book written for the lay public explaining advanced aspects of heart disease.

In his role at St. Joseph’s Hospital, Dr. Superko continued his research to identify patients’ genetic susceptibility to heart disease, cancer and other chronic disease states. A co-founder of BHL, Dr. Superko will serve as Vice President of Medical Affairs where he will be the key medical spokesperson for the company’s products and services and the key liaison with physician and research collaborators, including academic medical centers, pharmaceutical companies, and the FDA.

“Superko will bring his deep scientific knowledge, world-renowned reputation, and great passion for understanding the genetic basis of cardiovascular disease to the company,” noted Tom Callaway, President of Life Science Partner.  “There is no better person to prepare Celera’s market for the emerging revolution in personalized disease management.”

Dr. Superko earned his Bachelor of Science degree in Biology from University of California, San Diego, and his Medical degree from the State University of New York, Stony Brook.  He completed his Internship and Fellowship in Internal Medicine at the University of California, Davis.

Life Science Partner recruits founder of Pathway Diagnostics and former head of Research and Development at Specialty Laboratories.

Life Science Partner announces the recruitment of Meeta Patnaik, MD, formerly Senior Vice President of Predictive Diagnostics at PGX Health, LLC, a Division of Clinical Data, to the Laboratory Corporation of America (LabCorp). 

LabCorp is one of the world’s largest clinical laboratory networks with scientific expertise in esoteric testing, genomics, and clinical and anatomic pathology.  LabCorp performs more than one million tests on approximately 400,000 samples each day.  LabCorp is a pioneer in the commercialization of new diagnostic technologies, with more than 35 years of experience in serving physicians and their patients.Patnaik will lead LabCorp’s development of new companion diagnostics business.

In her recent role at PGX, Patnaik was responsible for leading all clinical, scientific and medical affairs in diagnostic initiatives for the company and oversight of the diagnostic pipeline through all phases of product development, from very early stage evaluation through collaborative development and commercial launch.

Patnaik is a serial entrepreneur and diagnostic scientist.  She was the founding vice President of Clinical Diagnostics for Pathway Diagnostics as well as formerly Vice President, Research and Development for Specialty Laboratories.

In her new role at LabCorp, Patnaik will be responsible for identify opportunities for exploiting LabCorp’s considerable expertise in companion diagnostics and developing and creating bridges between the academic partners and LabCorp’s pharmaceutical customers.

“Patnaik is a gifted scientist in the emerging field of companion diagnostics,” noted Tom Callaway, President of Life Science Partner.    “Her experience in building links between academic scientists, the clinical laboratory, and the pharmaceutical industry is unmatched.  Working closely with Chief Scientific Officer, Andrew Conrad, Patnaik will help LabCorp make a significant impact in the field.”

Patnaik earned her MBBS in Medicine at the S. C. B. Medical College in India and completed a Senior Fellowship in the Department of Infectious Diseases at the University of California in Los Angeles, CA.

Life Science Partner recruits Senior Cardiovascular Product Development Executive.

Life Science Partner announces the recruitment of Gene Jung, formerly Vice President of Engineering at ProRhythm, to the newly created Global Cardiovascular Innovation Center (GCIC) based in Cleveland, Ohio.

Headquartered on the campus of The Cleveland Clinic, GCIC was launched with a $60 million grant for the State of Ohio to develop and commercialize new cardiovascular products.  GCIC will utilize the considerable clinical, research and commercialization capabilities of the GCIC member organizations in northeast Ohio and focus on developing technologies in partnership with established cardiovascular-focused companies and in newly-formed start-up companies.

In Jung’s most recent role at ProRhythm, he was responsible for developing the company’s High Intensity Focused Ultrasound (HIFU) technology into a commercial product for Atrial Fibrillation.

Previously, Jung was a Medical Device Consultant in Tokyo where he designed and developed intra-vascular coronary products for numerous Japanese Medical Device Companies.   Prior to his work in Japan, Jung served as Research and Development Director at the Image Guided Therapy Division at Jomed Corporation in San Diego.

“Jung has a broad view of medical device technology from early-stage physician-driven innovation though product commercialization,” noted Tom Callaway, MD, founder and president of Life Science Partner. “His extensive technical leadership background across multiple cardiovascular platforms and his strong industry and physician networks will serve GCIC well.”

Jung earned his Bachelor of Science Degree in Mechanical Engineering from the University of Arizona in Tucson, AZ.

Life Science Partner recruits Innovative R&D Scientist.

Life Science Partner announces the recruitment of Shubhayu Basu, PhD, formerly Group Lead for New Business Ventures at Abbott Vascular, to the newly created Global Cardiovascular Innovation Center (GCIC) based in Cleveland, Ohio.

The organization was launched with a $60 million grant for the State of Ohio to develop and commercialize new cardiovascular products.  GCIC will focus on developing technologies in partnership with established cardiovascular-focused companies and in newly-formed start-up companies.

In Basu’s former role at Abbott Vascular (formerly Guidant), he was responsible for creating and implementing processes for identifying emerging technologies and various disease spaces and opportunities against the company portfolio and growth landscape.   Previously, he served as Group Lead, Research and Development, Cardiac Therapies for the company.

Prior to joining Guidant/Abbott, Basu was a Biodesign Innovation Fellow at Stanford University’s Biodesign Program in Palo Alto, CA.

“Basu will join another LSP recruit – Gene Jung – who shares his passion about new technologies and their application in patient care,” noted Tom Callaway, MD, founder and president of Life Science Partner.  “His ability to work with complex technologies to identify commercial opportunities and to oversee their development is a perfect fit for the GCIC team.”

Basu earned both his Bachelor and Masters Degree of Technology in Biochemical Engineering and Biotechnology at the Institute of Technology in New Delhi, India.  He received his PhD in Chemical Engineering at the Ohio State University in Columbus.

Life Science Partner recruits former Senior Vice President, Business and Commercial Development from ACADIA Pharmaceuticals

Life Science Partner announces the recruitment of Brian Lundstrom, an experienced biopharmaceutical business development executive, to Windy Hill Medical to become Chief Executive Officer for the company.

Windy Hill Medical is a California-based medical device and pharmaceutical company focused on the development of products to reduce the risk of developing breast cancer in patients deemed to be at high risk.

In Lundstrom’s previous role at ACADIA, a San Diego-based biopharmaceutical company developing small molecule therapeutics for the central nervous system, he was responsible for developing partnerships, particularly with Asian and European pharmaceutical companies, for the company’s four clinical-stage and preclinical programs.

Prior to joining ACADIA, Lundstrom served as Vice President of Business Development and Humanized Polyclonal Antibody Program Manager for Genzyme Corporation in the areas of Oncology, Hematology Transplantation and Immunology. 

In his new role as Chief Executive Officer, he will lead the Company through an additional round of financing, the development and expansion of the clinical trial program, and commercialization of its product portfolio.

“Lundstrom is an experienced and effective global biopharmaceutical manager with a broad background in business development and partnering,” noted Tom Callaway, MD, founder and president of Life Science Partner.  “With his passion and experience, he will serve Windy Hill well in its mission to bring lasting improvements for patients with early-stage breast cancer.”

Lundstrom earned his Master of Science degree in Chemical Engineering with an immunology and molecular biology focus from the Danish Technical University in Lyngby, Denmark.  He attended the Copenhagen Business School and earned a diploma in Economics in International Management.  Lundstrom received his PhD in Biochemistry from Odense University and then attended the Monterey Institute of International Studies in Monterey, CA for an MBA program.

Learn More About Life Science Partner

Click button below to learn more about how we recruit Chief Executives:

Life Science Partner recruits former Vice President, Preclinical Development for Angiotech and Aptuit.

Life Science Partner announces the recruitment of Andrew Penman, an experienced scientist and preclinical development executive, to the Southern Research Institute in Birmingham, Alabama.

Southern Research Institute is an independent, not-for-profit center for scientific research providing innovative leadership in scientific discovery and drug development.  With a focus on the discovery and advancement of new, small-molecule therapeutics from the design stage to the clinic, Southern Research Institute’s Drug Discovery Research Division has accomplished innovative research in the areas of cancer, infectious disease and neuroscience.

Andrew Penman Alabama

Most recently, Penman was the Vice President of Preclinical Development for Angiotech, a global specialty pharmaceutical and medical device company, where he was responsible for managing the global preclinical business in research and development for the company.

Previously, Penman served as President of Preclinical Technologies at Aptuit (formerly Quintiles, Inc).  In his role at the Southern Research Institute, he will be responsible for providing scientific vision, strategic direction and operational management of the Drug Development Division of the Institute.

“Penman is a talented preclinical pharmaceutical development executive with broad experience in infectious diseases, oncology and cardiology drugs,” noted Tom Callaway, President of Life Science Partner. “He will successfully build upon the Institute’s considerable scientific expertise and drug development platform and further enhance their reputation as one of the nation’s premier drug discovery organizations.”

Penman received his undergraduate degree in Chemistry from the Heriot-Watt University in Edinburgh, Scotland and earned his PhD from the University of Kent in Canterbury, Kent.

Life Science Partner recruits former Senior Vice President, Sales and Marketing for Vermillion.

Life Science Partner announces the recruitment of Steve Lundy, a top commercial executive in early-stage diagnostics companies, to MicroPhage, an early-stage company based in Longmont, Colorado. 

Using its proprietary bacteriophage-based technology, MicroPhage is developing rapid assays for the direct identification and drug susceptibility of deadly bacterial strains such as Methicillin Resistant Staphylococcus Aureus (MRSA).

Most recently, Lundy was the Senior Vice President of Sales and Marketing for Vermillion, where he helped lead the company’s transformation from life sciences to a clinical diagnostics business model.

Lundy previously served as Vice President of Sales, Marketing and Business Development for GeneOhm Sciences.  He led the launch of the IDI-MRSA(TM) assay, the first nucleic-acid based test to be cleared by regulatory agencies to replace conventional microbiological culture by directly testing the clinical specimen. GeneOhm was acquired by BD (Becton, Dickinson and Company) in 2006.

“Lundy is a seasoned diagnostics industry leader who understands the market and the opportunity,” noted Tom Callaway, MD, President and Founder of Life Science Partner.  “He brings an unsurpassed depth of experience in infectious disease  diagnostics from GeneOhm to capitalize upon MicroPhage’s novel platform for MRSA detection.”

Lundy received his Bachelor of Science degree from the United States Air Force Academy in Colorado.

Learn More About Life Science Partner

Click button below to learn more about how we recruit Chief Executives:

Life Science Partner recruits senior biotechnology entrepreneurial and Co-Founder and Chairman of North Carolina Innovation Foundation.

Life Science Partner announces the recruitment of Max Wallace, a biotechnology CEO and innovative leader, to lead Accelerate Brain Cancer Cure, Inc.

ABC2 is a not-for-profit organization established in 2001 with a for-profit mindset and a singular focus: to hasten the discovery of a cure for brain cancer.  Founded by the Case , the ABC2 has an entrepreneurial model of identifying and funding critical research into brain cancer and catalyzing interdisciplinary collaboration works.

Wallace shares the ABC2 passion for using a not-for-profit model for pushing forward new drug development – particularly to treat diseases ignored by big pharma companies due to low prevalence and smaller markets.

Max Wallace is Chief Executive Officer of TheraLogics, an early-stage biopharmaceutical company based on technology developed by Dr. Albert Baldwin at the University of North Carolina.  He previously co-founded and served as President of Trimeris, a public biopharmaceutical company that created and brought to market the world’s first entry inhibitor, establishing a new class of drugs for HIV/AIDS and other viral diseases.  He also founded and developed several other biopharmaceutical companies, including Sphinx Pharmaceuticals Corporation (now a division of Eli Lilly & Co); SARCO (now a part of PPD/Pharmaco); and Cogent Neuroscience.

“Max is a dynamic leader who knows how to bring a team together and motivate them around a common goal,” noted Tom Callaway, MD, founder and president of Life Science Partner.  “He will bring his exceptional entrepreneurial instincts and innovative not-for-profit expertise together to provide the visionary and strategic leadership needed to fulfill ABC’s important mission.”

Wallace received his Bachelors degree Duke University and earned his law degree from the University of Florida College of Law in Gainesville, Florida.

Learn More About Life Science Partner

Click button below to learn more about how we recruit Chief Executives:

Life Science Partner recruits former Oncology Regulatory Officer for Johnson & Johnson, Pharmaceutical and Research & Development.

Life Science Partner announces the recruitment of Steve Hamburger, a global regulatory and drug development executive, to Exoxemis, Inc.

Exoxemis is an early-stage biopharmaceutical research and development company focused on prevention and treatment of serious infections and the significant and growing problem of microbial drug resistance.  The company’s myeloperoxidase (MPO) technology is a versatile platform that can be leveraged into multiple product areas, including medical, biodefense, industrial, veterinary, disinfectant, and agricultural applications.

In Hamburger’s most recent role at J & J, he was responsible for a cross-functional regulatory and drug development team and served as a global regulatory officer for the Oncology and Hematology division.  His portfolio included the key biologic PROCRIT.  Previously, he served in a similar role as the strategic and operational leader for the anti-cancer drug DOXIL.  Prior to his tenure at J & J, Hamburger was Senior Regulatory Research Scientist, Oncology and US Regulatory Affairs for Eli Lilly and Company.

“Steve is an experienced regulatory strategist with a broad therapeutic background in the pharmaceutical industry including the areas of infectious diseases, cardiology and oncology,” noted Tom Callaway, MD, founder and president of Life Science Partner.  “He’s a passionate and self-directed individual with a long track record of successful interactions with key global health authorities that will greatly benefit Exoxemis’ platform and opportunity.”

Hamburger received his Bachelor of Science degree in General Science and Biochemistry from the University of Iowa in Iowa City.   He earned a Master of Science in Biology from Butler University in Indianapolis, Indiana and his PhD in Pharmacology and Toxicology from the Indiana University School of Medicine.

Life Science Partner recruits former VP of Finance & Administration and Principal Accounting Officer of AtheroGenics, Inc.

Life Science Partner announces the recruitment of Charles Deignan, an experienced pharmaceutical finance executive, to Metastatix, Inc.

Metastatix is an emerging pharmaceutical company developing and commercializing effective, convenient and safe small-molecule drugs for a broad portfolio of indications including cancer, HIV infection and inflammation. The company’s initial focus has been on the CXCR4 receptor, a critical mediator of cellular and chemical trafficking.

Deignan was most recently Vice President of Finance & Administration and Principal Accounting Officer for AtheroGenics, Inc., an emerging pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceutical products for the treatment of chronic inflammatory diseases.

In this role, he was responsible for all areas of finance and accounting, as well as risk management, information systems and human resources for the company.  Previously, Deignan was Division Controller for AAI Pharma, Inc. in Wilmington, North Carolina where, among other financial responsibilities, he directed the financial reporting related to the company’s IPO.

“Deignan is a proven, roll-up-your-sleeves financial executive who understands the challenges of an early-stage company,” noted Tom Callaway, MD, founder and president of Life Science Partner.  “In addition, he brings many other skill sets to the company with his demonstrated experience in human resources, information technology and clinical trials contracting and management.”

Metastatix recently raised a $35M Series B round from a nationally recognized group of venture investors including Frazier Healthcare Ventures, HIG Ventures, SROne, Aruna, and Georgia Venture Partners.

Deignan earned his Bachelor of Science degree in Business Administration from Boston University’s School of Management and is a Certified Managerial Accountant.